Summary
BeiGene, Ltd. (ONC) reported a significant increase in total revenues for the third quarter of 2024, reaching $1,001.6 million, up 28.2% year-over-year, driven primarily by strong product revenue growth. Product revenue surged by 66.9% to $993.4 million, largely fueled by the exceptional performance of BRUKINSA, which saw a 93.0% increase in global sales, particularly in the U.S. and Europe. Despite a substantial increase in operating expenses, the company managed to reduce its net loss. While collaboration revenue decreased significantly due to prior-year terminations, the robust growth in product sales underscores the increasing market acceptance and commercial success of BeiGene's key oncology medicines. The company continues to invest heavily in research and development, with R&D expenses increasing by 9.5% to $496.2 million, reflecting its commitment to pipeline advancement. Selling, general, and administrative expenses also saw an increase of 24.5% to $455.2 million, supporting the global commercial expansion. BeiGene ended the quarter with a healthy cash position of $2,701.9 million, providing ample liquidity for ongoing operations and future growth initiatives. Investors should note the ongoing legal proceedings related to patent infringement and trade secrets, which could present future risks.
Financial Highlights
48 data points| Revenue | $1.00B |
| Gross Profit | $831.14M |
| R&D Expenses | $496.18M |
| SG&A Expenses | $455.22M |
| Operating Expenses | $951.40M |
| Operating Income | -$120.27M |
| Interest Expense | $14.31M |
| Net Income | -$121.35M |
| EPS (Basic) | $-0.09 |
| EPS (Diluted) | $-0.09 |
| Shares Outstanding (Basic) | 1.38B |
| Shares Outstanding (Diluted) | 1.38B |
Key Highlights
- 1Total revenues grew 28.2% year-over-year to $1,001.6 million in Q3 2024.
- 2Product revenue increased 66.9% year-over-year to $993.4 million, driven by BRUKINSA's strong performance.
- 3BRUKINSA global revenue reached $690.3 million, a 93.0% increase compared to the prior year.
- 4Research and development expenses increased by 9.5% to $496.2 million.
- 5Selling, general, and administrative expenses increased by 24.5% to $455.2 million.
- 6The company ended the quarter with $2,701.9 million in cash, cash equivalents, and restricted cash.
- 7BeiGene continues to expand its pipeline, with four new molecular entities entering the clinic this quarter.